5 completed, 3 terminated, 2 recruiting, 1 active not recruiting. 8 Phase 1, 4 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Terminated 3, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Not applicable | 1 | Completed 1 |
Follow Anti-PD1: new trials by email Literature Review of Anti-PD1 trials Research Report on Anti-PD1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT EWSR1 immunotherapy, Pembrolizumab - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | Phase 1 | Not yet recruiting | Rabi Hanna | 24 | 2026-10-01 | 2026-09-17 |
| Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma Anti-PD1, Anti-PD1 combined with Becotatug Vedotin - Nasopharyngeal Cancinoma (NPC) | Phase 3 | Recruiting | Sun Yat-sen University | 86 | 2026-07-20 | 2026-07-15 |
| Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma Anti-PD1, asparaginase - Nasopharyngeal Carcinoma (NPC) | Not applicable | Completed | Chang Gung Memorial Hospital | 8 | 2023-08-01 | 2024-11-07 |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma BCD-217, anti-PD1, Excision of the primary lesion - Melanoma Stage III, Melanoma (Skin) | Phase 3 | Active not recruiting | Biocad | 411 | 2023-04-05 | 2025-07-08 |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG rHSC-DIPGVax, Balstilimab, Zalifrelimab - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 36 | 2022-01-10 | 2026-03-17 |
| Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. PF-07062119, Anti-PD1, Anti-VEGF - Gastrointestinal Tumors, Colorectal Adenocarcinomas | Phase 1 | Terminated | Pfizer | 79 | 2019-11-19 | 2025-01-16 |
| Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma Nivolumab, Anti-GITR Monoclonal Antibody MK-4166, IDO1 inhibitor INCB024360 - Glioblastoma, Glioblastoma Multiforme | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 3 | 2019-03-22 | 2020-07-02 |
| A Study of CS1002 in Subjects with Advanced Solid Tumors CS1002, CS1003 - Solid Tumor, Adult | Phase 1 | Completed | CStone Pharmaceuticals | 91 | 2018-04-26 | 2024-09-19 |
| Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer IMM-101, Gemcitabine, Nab-paclitaxel - Metastatic Cancer | Phase 1 / Phase 2 | Terminated | Immodulon Therapeutics Ltd | 2 | 2017-05-31 | 2024-11-25 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread BMS-986205, Nivolumab, Ipilimumab - Advanced Cancer, Melanoma | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 627 | 2016-04-14 | 2023-08-28 |
| Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma Radiotherapy, Rituximab, Autologous dendritic cells - Follicular Lymphoma | Phase 2 | Completed | Oslo University Hospital | 10 | 2016-01-01 | 2021-03-01 |
| A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors Lirilumab, Nivolumab, Ipilimumab - CANCER,NOS | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 337 | 2012-10-07 | 2023-02-02 |
Melanoma (3) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Desmoplastic Small Round Cell Tumor (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Diffuse Intrinsic Pontine Glioma (1) · Digestive System Neoplasms (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Lymphoma, Follicular (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Sarcoma (1)
Bristol-Myers Squibb (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Biocad (1) · CStone Pharmaceuticals (1) · Chang Gung Memorial Hospital (1) · Immodulon Therapeutics Ltd (1) · Oslo University Hospital (1) · Pfizer (1) · Rabi Hanna (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sun Yat-sen University (1)
United States (6) · Australia (3) · France (3) · Canada (2) · Italy (2) · Norway (2) · Spain (2) · Belarus (1) · China (1) · Finland (1) · Germany (1) · Hong Kong (1) · Japan (1) · Poland (1) · Russia (1)
Arne Kolstad, MD PhD (1) · Ashley Plant-Fox, MD (1) · David Cunningham, MD FRCP (1) · Huang-Yu Yang, M.D./Ph.D (1) · Matteo Trucco, MD (1) · Michael Lim, MD (1) · Peter M Anderson, MD, PhD (1) · Rabi Hanna, MD (1) · Timothy A Chan, MD, PhD (1) · Wanmei Wang (1)
2015 (1), 2016 (1)